{"name":"Luye Pharma Group Ltd.","slug":"luye-pharma-group-ltd","ticker":"","exchange":"","domain":"luye.cn","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"INVEGA SUSTENNA","genericName":"INVEGA SUSTENNA","slug":"invega-sustenna","indication":"Other","status":"marketed"},{"name":"LY06006","genericName":"LY06006","slug":"ly06006","indication":"Other","status":"phase_3"},{"name":"Placebo, extended-release microspheres","genericName":"Placebo, extended-release microspheres","slug":"placebo-extended-release-microspheres","indication":"Other","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"LY09004","genericName":"LY09004","slug":"ly09004","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"LY01011","genericName":"LY01011","slug":"ly01011","indication":"Type 2 diabetes mellitus","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"EU-Prolia","genericName":"EU-Prolia","slug":"eu-prolia","indication":"Osteoporosis in postmenopausal women","status":"phase_3"},{"name":"LY01005","genericName":"LY01005","slug":"ly01005","indication":"Cancer (specific indication under investigation in phase 3 trials)","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"LY03005 extended-release tablet","genericName":"LY03005 extended-release tablet","slug":"ly03005-extended-release-tablet","indication":"Schizophrenia","status":"phase_3"}]}],"pipeline":[{"name":"LY09004","genericName":"LY09004","slug":"ly09004","phase":"phase_3","mechanism":"LY09004 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"EU-Prolia","genericName":"EU-Prolia","slug":"eu-prolia","phase":"phase_3","mechanism":"EU-Prolia is a monoclonal antibody that inhibits RANKL (receptor activator of nuclear factor kappa-B ligand) to reduce osteoclast formation and bone resorption.","indications":["Osteoporosis in postmenopausal women","Bone loss in patients with cancer or receiving cancer therapy"],"catalyst":""},{"name":"INVEGA SUSTENNA","genericName":"INVEGA SUSTENNA","slug":"invega-sustenna","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY01005","genericName":"LY01005","slug":"ly01005","phase":"phase_3","mechanism":"LY01005 is a small-molecule inhibitor that targets specific intracellular signaling pathways involved in cell proliferation and survival.","indications":["Cancer (specific indication under investigation in phase 3 trials)"],"catalyst":""},{"name":"LY01011","genericName":"LY01011","slug":"ly01011","phase":"phase_3","mechanism":"LY01011 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"LY03005 extended-release tablet","genericName":"LY03005 extended-release tablet","slug":"ly03005-extended-release-tablet","phase":"phase_3","mechanism":"LY03005 is a dopamine D2 receptor antagonist that blocks dopamine signaling in the central nervous system.","indications":["Schizophrenia","Bipolar disorder"],"catalyst":""},{"name":"LY06006","genericName":"LY06006","slug":"ly06006","phase":"phase_3","mechanism":"LY06006 is a small-molecule inhibitor that targets specific intracellular signaling pathways involved in disease pathogenesis.","indications":[],"catalyst":""},{"name":"Placebo, extended-release microspheres","genericName":"Placebo, extended-release microspheres","slug":"placebo-extended-release-microspheres","phase":"phase_3","mechanism":"This drug is a placebo, meaning it has no active therapeutic effect.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTE5xdHkwaXNZS3dhak1pR0kwdHVkOG9zRS1OV25hRlg3RDJGN1RHYzVpa1V5dXVqNG1HdGZEbUtZYi1wS3JFd3RYM0JhWHZlbTlkck9xbGFkcw?oc=5","date":"2026-04-05","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Price performance - Yahoo Finance Singapore","headline":"Price performance","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-04","type":"earnings","source":"simplywall.st","summary":"Luye Pharma Group (SEHK:2186) Valuation After Earnings Growth And Surprise 2025 Dividend Decision - simplywall.st","headline":"Luye Pharma Group (SEHK:2186) Valuation After Earnings Growth And Surprise 2025 Dividend Decision","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxPNi1rSVA1MGVzUXd6UTV3Vmd1UUtKOUQ3NXBnU1VLV29NM2NrSW15QnA2aHVGN0F6LWFoZFZEMEhSUWEta1pNS3VRcUJIZ2p3d0lJMHRYQ19SRnZCdjU5NXhFMDVnOWNudXdMWFl6djB1RUxwU0dxenJ1SUIzb21xS3BJOTl1cjVjTU1ZZTNOMjJWWVVJMS1qTnlOVmNraXdsQS0tc0hybWNRa05RelA1UWRQdU9hN2lmWkVvbDhQUTFLV1JhX3ZFanpJbFdlUQ?oc=5","date":"2026-03-31","type":"pipeline","source":"TradingView","summary":"Luye Pharma Group Posts FY Net Income Attributable RMB618.7 MLN - TradingView","headline":"Luye Pharma Group Posts FY Net Income Attributable RMB618.7 MLN","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQTHpyTzRPZS1hVFpuUXl3Tm0xWUZTclJuY1ZiZzNlUVR0b2ZNWXc3Y0pWT2l5WFkzdzNMM1ltYlliVjZTaGNkaUVqNzdKbk9OMG5aWFNHMDJ1TE1XWGxEYkJqQmJ0MmRlZjc3UWxPY0xobU5YbHNCeWJjWi1Pd0hSdmlzQ2xvRjJ1QUdTdzlNOU1SRVZVYkhDV3RCaVloX29tdC1BMUg3eVRUVi1wdVNjOFBGX1A3Y3dG?oc=5","date":"2026-03-31","type":"pipeline","source":"marketscreener.com","summary":"Luye Pharma Group posts FY net income attributable RMB 618.7 mln - marketscreener.com","headline":"Luye Pharma Group posts FY net income attributable RMB 618.7 mln","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQNkZwQ3FDVUZ5eEluMHBpbGNOZkpWUTNmUnV3bEFkaTZXejZYNU1KdnM5VUJVcEdHMkxmaE10ZTVkb3NiTnZEQmpIbnJpZEZIVTBOci1kNmlyS2ZNVGNoU2k2YlpxUUR1TGtzdWlqamV6dFNfUEVDYWhicTZ5RXpiZkpWZll2UThTeWNwYjVfcDRLeENJWHhsenpqT29GNXNXc0ZtVE1HN29EdFFyRkdzYi1hdzl0bmdVSlpGZkJBVlZFVl9v?oc=5","date":"2026-03-30","type":"earnings","source":"TipRanks","summary":"Luye Pharma Delivers Double-Digit Profit Growth in 2025 but Skips Dividend - TipRanks","headline":"Luye Pharma Delivers Double-Digit Profit Growth in 2025 but Skips Dividend","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOMVZDTURHN1FnN2hCOWtSbk1oUzJIbXBXUXJ2a201MU9NZHlBcklHcHRJZ2VEOERKbkY3SHpOUXZCdXZ5UEgyZUUxNW1ybFpxUTVScWhha0NXS1hMb290NkVPMXQ1c1kzcGRWUnN6a0tLOVNWZmZzaVZCS3dtTGxZY21LbHpfZXRaaGVXaG4tVXE4MFh5eUFwaUdFYUs0MUwwNDZJcGp6ODhvdlpnSEU0clhMWWNMSlAt?oc=5","date":"2026-03-17","type":"regulatory","source":"TipRanks","summary":"Luye Pharma Sets March 2026 Board Meeting to Approve 2025 Results - TipRanks","headline":"Luye Pharma Sets March 2026 Board Meeting to Approve 2025 Results","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNNVJIT09uendORkpVSU1lOW0yejNBLXlFdmd4dmEwRjlZaTZvMm1FNFUzSWI5VGdnZVN2eC1JQlUyS2VQN1RrcWRjNGhIb3hCX0FOSmFOTnVkNmkwemN2VlUwa0ZVWUd2WC1JLWZ3RzJSdV82cVJqNjZjaW1WU3JKQQ?oc=5","date":"2025-12-15","type":"regulatory","source":"Fact.MR","summary":"Demand for Transdermal Skin Patches in USA | Global Market Analysis Report - 2035 - Fact.MR","headline":"Demand for Transdermal Skin Patches in USA | Global Market Analysis Report - 2035","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNWlFHUF9yTEhwaldfbG5KT1VtWVMtR012bmZuSkRSNzgxZ05hTkM5S1F2QjE5bWUyeW5nX2RFWWVXa2FRU2dibFNIMUdBRXV2eWluNkotT19nSzVWUkMwOU82a3ZUQ3RwalJaMDQxcW5UZzRZU1c1Sk9SU2dzb2FEeGZjU3EtaG52SlQxNlNkM2hhS3NhbkE4MV9iaVZWcjQxZ09tOVYxUndwX2kzdVUw?oc=5","date":"2024-10-22","type":"deal","source":"Bloomberg.com","summary":"Richard Ong's RRJ Buys $150 Million Luye Bonds, First China Deal Since 2019 - Bloomberg.com","headline":"Richard Ong's RRJ Buys $150 Million Luye Bonds, First China Deal Since 2019","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgJBVV95cUxOX3hfUEFxSEdKUktReWZBSlBaYWM2T0lCRnQtYXhBUnp2VmdXRDBPSXBQNEl6cW9RUDlTdUltcFQzRHBnTUp4QUJjeVNyeXk0ZmV1NUptdHFJT3FSNmhYOEdBXy1kanRvZi0zS3ZKZjEyY0liMXMyeTVUbDRyVURMVE1ZbG0tN2o0Mm0zLW9ndmUxdUtyZmZYeHc2aTEzc0NVdmxMLUFsbnR4RWJkVm1NdmxSS0tSdTN5MVMxTjhkSjhDYzVaTEp3bkJ5NjIxWGg2d2pFUFY4bE5jYV9oNkJsTEo0YVVUS3hMWDFXdm83QzZxanVuSmNpbTNEcnlSemlscVdYZldUYkFyYXdCM2QzNUlRWDV2dw?oc=5","date":"2024-02-05","type":"pipeline","source":"PR Newswire","summary":"Luye Pharma Grants Myung In Pharm Exclusive Rights to Commercialize Rivastigmine Twice Weekly Transdermal Patch in South Korea - PR Newswire","headline":"Luye Pharma Grants Myung In Pharm Exclusive Rights to Commercialize Rivastigmine Twice Weekly Transdermal Patch in South","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwJBVV95cUxPSzAyUjBHMmx2eFQ1ODB6QnYxV2lHQllIaWcwekhkVGNOaUdxVnppdU1TckwxYm1tRlZQV3d4clBhVHRlTHNUd08zdGU2WFhPOWM2ZTQ1TWUyb1RhQ1IyenhrWUdGSFJfX0ZLcHhEcHZmREotWVZab0JKWFhjMUZNRENJQ0tGcjM3YjRMNmlUbDh5ejIyQzdSUDVreHRId091Rm1QeGdwLUEtX3RJSjItcHhyb0YtaVlaUXY0T1pxNHBJVnV5djF4c1RuNVZKbkt0YWNRYmEzbGF3ZTlGa2w5blJUWTZjSDk0R0ZaRXZkeWtfdlRvb3BaYjBybVkzNThKU1ExdnhqNENmbnNadmhwM0lwU2RneEg2VkZtWVo2QzJ2Zk9BdkRaNldfOEtCanU5TGVzQlVJcHI3dnRxWU10UXREMk44UExzNTBfcWxJcw?oc=5","date":"2021-03-16","type":"pipeline","source":"businesswire.com","summary":"Italfarmaco Group Enters Into an Agreement with Luye Pharma to Commercialize Alzheimer’s Disease Treatment Rivastigmine Multi-Day Transdermal Patch in Four European Countries - businesswire.com","headline":"Italfarmaco Group Enters Into an Agreement with Luye Pharma to Commercialize Alzheimer’s Disease Treatment Rivastigmine ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxQUzBsRVA0anJhNmhUci1Xa0dZNHU0amNzeVl3Y2FCb3ltU2dXX0U3ZmgtbENfd2hSbFlmMFRJUVJheS1jXzBZd016cXNHVjdqdWR0c1lZeUNUSlAwUFJaTUtjUmw0aEN0dG5wT1pOQkZ1Y0pMQjEyR3AwSGVfWXFvbmNqVE15b1JXSEgxVlEtNkFTUkNPUHdZOFdPYWdlT2J3ZEFGaE5leTdKSGVHY3FwazRNTVJnMm11TmozWUdUem12eTJ4YlpCVW5iN1R6U1hRbWc0Wk45eVNYUUE2Tkw3bklMU2FrRTVid0VxSWFDS1pHMmVjZXR0Z0hIWWZqZ3BicHpVNmZtWnVheGd5eGNNaE9sQllSS001NUVUZjlBbmxnXzF2NjhxWU5n?oc=5","date":"2018-05-07","type":"pipeline","source":"AstraZeneca","summary":"AstraZeneca and Luye Pharma Group enter agreement for rights to Seroquel and Seroquel XR in the UK, China and other international markets - AstraZeneca","headline":"AstraZeneca and Luye Pharma Group enter agreement for rights to Seroquel and Seroquel XR in the UK, China and other inte","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQdHRZNEtfZ2QyeDZheGFlYkFXVm5YOFFPSjJkYzFFb0JJUG5lQ0M1VkpMSUstN05jT0c2M3ZVLTVVZ1JKYU9Vc1UzMXdCblMzbHlOZUx5Rm9YY0d5eFdzdEFnYW8ydHdZSXJNdHQwcVNwSk5VbFZVWlJBbjBMd0xlUHdkQlFJa1lxY08yeEpZUWVURWg0aFE?oc=5","date":"2018-05-07","type":"pipeline","source":"BioPharma Dive","summary":"AstraZeneca sells off foreign rights to Seroquel - BioPharma Dive","headline":"AstraZeneca sells off foreign rights to Seroquel","sentiment":"neutral"}],"patents":[],"drugCount":8,"phaseCounts":{"phase_3":7,"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}